Group 1: Company Performance - The company achieved a revenue of 4.137 billion CNY in Q3, with a cumulative total of 12.813 billion CNY for the year, representing a year-on-year growth of 6.55% [2] - Net profit attributable to shareholders was 181 million CNY in Q3, totaling 686 million CNY for the year, reflecting a growth of 1.26% year-on-year [2] - The net cash flow from operating activities was 1.341 billion CNY, with total assets amounting to 16.322 billion CNY and net assets attributable to shareholders at 7.870 billion CNY [2] Group 2: Store Expansion and Market Coverage - The company operates 10,008 directly-operated stores, with a net increase of 802 stores since the beginning of the year [2] - Stores in Yunnan province number 5,358, accounting for 53.54% of total stores, while non-Yunnan stores total 4,650, representing 46.46% [2] - The company is focusing on expanding its presence in key regions such as Sichuan and Chongqing, which account for 42.65% of total stores with 1,983 locations [3] Group 3: Challenges and Market Conditions - The company faces pressure from policy changes regarding health products, particularly in Kunming, where health products have been restricted from being purchased with medical insurance since January 2023 [3] - A new policy in Kunming aims to alleviate the medication burden for chronic disease patients, impacting sales due to the absence of certain products [3] - The company has 1,231 chronic disease stores and 735 outpatient coordination stores, with pricing policies affecting gross margins [3] Group 4: Strategic Measures for Improvement - The company plans to enhance non-insurance product sales and increase store numbers outside Yunnan to mitigate policy impacts [4] - Focus on improving transaction frequency and customer volume through better disease management services and seamless online-offline integration [4] - Emphasis on efficient supply chain management and inventory turnover to optimize product promotion and reduce operational cycles [4] Group 5: Future Outlook and Business Strategy - The company is actively pursuing franchise opportunities and has integrated the operations of acquired entities to enhance delivery efficiency [7] - Non-pharmaceutical health products are identified as a key growth area, with a focus on personal care and maternal-infant products [11] - The company aims to improve overall profitability through enhanced store group management and supply chain optimization [14]

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 编号：TG202310-001 ■特定对象调研 □分析师会议 □媒体采访 业绩说明会 投资者关系活动类别 □新闻发布会 路演活动 □现场参观 ■其他 （电话会议） 参与单位名称及人员 东北证券 刘宇腾 文将儒、中信证券 沈睦钧 郭羽、上海 国赞 郭玉磊、东方基金 邵子馨等投资者140 人 姓名 时间 2023年10 月31日 13:30-14:45 地点 一心堂药业集团股份有限公司总部 副总裁兼董事会秘书 李正红、证券总监兼证券事务代表 公司接待人员姓名 肖冬磊、证券事务代表 阴贯香 投资者关系活动主要 公司2023年三季报业绩交流会 内容介绍 附件清单（如有） 投资者调研会议记录 ...

Cash Flow and Financial Performance - The company's cash inflow from operating activities reached CNY 12,459,421,828.66, an increase from CNY 11,484,595,842.87 in the previous year, reflecting a growth of approximately 8.5%[21] - The net cash flow from operating activities was CNY 1,340,703,243.26, a decrease of about 9.2% compared to CNY 1,477,301,792.16 in the same period last year[21] - The company reported a significant decrease in cash received from investment activities, with CNY 667,554.40 in the current period compared to CNY 6,947,000.00 in the previous year, marking a decline of 90.39%[7] - The total cash received from other investment-related activities was CNY 37,800,231.75, a substantial increase from CNY 58.47 in the previous year, indicating a growth of 64648834.07%[7] - The company disposed of fixed assets and received a net cash inflow of CNY 23,140,629.20, a remarkable increase of 7184.05% from CNY 317,688.90 in the previous year[7] - Cash inflow from investment activities totaled ¥61,608,415.35, a significant decrease from ¥1,207,552,247.37 in the previous period[22] - Cash outflow for investment activities reached ¥360,650,193.94, compared to ¥1,187,685,921.26 in the prior period, resulting in a net cash flow from investment activities of -¥299,041,778.59[22] - Total cash inflow from financing activities was ¥469,085,282.36, up from ¥250,008,756.05 in the previous period[22] - Cash outflow for financing activities increased to ¥1,557,557,768.38 from ¥1,112,346,321.34, leading to a net cash flow from financing activities of -¥1,088,472,486.02[22] - The net increase in cash and cash equivalents was -¥46,387,004.57, contrasting with an increase of ¥635,284,039.19 in the previous period[22] - The cash flow from operating activities showed a significant increase, indicating better liquidity management and operational efficiency[45] - The cash and cash equivalents decreased by 107.30% to approximately -¥46.39 million, influenced by asset disposals and significant investments[52] Revenue and Profitability - The total operating revenue for the current period reached ¥12,812,828,974.03, an increase of 6.55% compared to ¥12,025,419,077.72 in the previous period[45] - The operating profit for the current period was ¥786,496,404.26, up from ¥746,374,123.24 in the previous period, reflecting a growth of 5.4%[37] - The net profit attributable to shareholders of the parent company was ¥685,920,712.36, compared to ¥677,365,857.29 in the previous period, indicating an increase of 1.6%[38] - The total comprehensive income for the current period was ¥691,886,329.28, compared to ¥672,837,257.58 in the previous period, showing an increase of 2.5%[38] - Revenue for the reporting period reached ¥4,137,293,221.03, an increase of 1.89% year-over-year[80] - Net profit attributable to shareholders was ¥181,345,036.19, a decrease of 30.02% compared to the same period last year[80] - Net profit excluding non-recurring gains and losses was ¥174,048,756.36, down 30.33% year-over-year[80] - Basic earnings per share were ¥0.3050, reflecting a decline of 30.11% from the previous year[80] - Diluted earnings per share stood at ¥0.3053, a decrease of 29.93% compared to the same period last year[80] Assets and Liabilities - The total assets increased from CNY 16.18 billion at the beginning of 2023 to CNY 16.32 billion by September 30, 2023[74] - The total liabilities increased by 68.32% due to the expansion of traditional Chinese medicine business, indicating strategic growth initiatives[50] - The total liabilities decreased from CNY 8.65 billion at the beginning of 2023 to CNY 8.33 billion by September 30, 2023[74] - The company's equity attributable to shareholders increased from CNY 7.43 billion at the beginning of 2023 to CNY 7.87 billion by September 30, 2023[74] - Total assets at the end of the reporting period amounted to ¥16,321,717,499.21, an increase of 0.88% from the end of the previous year[80] - Shareholders' equity attributable to the parent company was ¥7,869,699,466.54, up 5.97% year-over-year[80] Investments and Research - The company plans to enhance customer engagement through CRM systems and personalized services, aiming to improve customer satisfaction and loyalty[44] - Research and development expenses increased to ¥7,649,444.02, up from ¥3,851,636.92, marking a rise of 98.5% as the company focuses on innovation[45] - Research and development expenses rose by 98.60% to approximately ¥7.65 million, reflecting the formation of new R&D projects[60] - The company established a research and development center in Chengdu to support digital transformation and market expansion[70] Operational Expansion - The company has established 13 logistics distribution centers, with the Yunnan warehouse being the largest, supporting over 5,000 stores in Yunnan and providing distribution capabilities to subsidiaries outside the province[13] - The company signed a share transfer agreement to acquire 100% equity of Shanghai Xuyuan Fire Technology Service Co., enhancing its logistics capabilities in the Shanghai region for pharmaceutical retail chain operations[13] - The total number of direct-operated stores increased by 802 to 10,008, with a notable expansion in non-Yunnan regions, particularly in the Sichuan-Chongqing area, which now accounts for 42.65% of the total store count[66] - The company plans to adjust its product categories to include health-related products, cosmetics, and personal care items to enhance market competitiveness[67] - The self-operated business will focus on filling service gaps and expanding the non-pharmaceutical supply chain[71] - The company plans to enhance the integration of O2O business with offline operations to improve operational efficiency[71] Miscellaneous - The effective membership count reached 41.8 million, contributing to a higher repurchase rate and solidifying the customer base for future growth[44] - Government subsidies recognized in the current period totaled ¥2,276,718.19, down from ¥12,561,517.27 previously[25] - Non-current asset disposal gains amounted to ¥8,239,907.53, compared to a loss of -¥2,930,486.73 in the previous period[25] - Cash received from minority shareholders increased significantly by 205,700.56% to approximately ¥18.02 million, indicating increased investment[52] - The total sales of the new retail business reached CNY 599 million from January to September 2023, with O2O business contributing CNY 483 million[71] - Accounts receivable decreased from CNY 1.73 billion at the beginning of 2023 to CNY 1.68 billion by September 30, 2023[72] - Inventory increased from CNY 3.39 billion at the beginning of 2023 to CNY 3.83 billion by September 30, 2023[73] - Prepayments rose by 44.09% to ¥12,790,882.76, driven by advances for leasing and franchise fees[28] - The construction in progress increased by 152.59% to ¥9,764,165.35, attributed to new projects initiated during the reporting period[28]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-081 号 一心堂药业集团股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一心堂药业集团股份有限公司（以下简称"公司"）第六届监事会第四次会议于 2023 年 10 月 30 日 9 时整在公司会议室召开，本次会议于 2023 年 10 月 19 日通过邮件和书 面形式发出通知。本次会议应出席会议的监事为 3 人，实际出席会议的监事为 3 人。本 次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 会议由冯萍女士主持。与会监事逐项审议了有关议案并做出决议如下。 二、监事会会议审议情况 1．审议通过《关于公司 2023 年第三季度报告的议案》 《2023年第三季度报告》具体内容详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）。并批准2023年第三季度财务报告对外报出。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 备查文件： 1、《一心堂药业集团股份有 ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-082 号 一心堂药业集团股份有限公司 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司（以下称"公司"）第六届董事会第四次会议于 2023 年 10 月 30 日 10 时以现场及通讯表决方式召开，本次会议于 2023 年 10 月 19 日通过邮 件及书面形式发出通知。本次会议应出席会议的董事为 9 人，实际出席会议的董事为 9 人。公司监事及非董事高级管理人员列席了会议。本次会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议如下。 二、董事会会议审议情况 1．审议通过《关于公司 2023 年第三季度报告的议案》 《2023年第三季度报告》具体内容详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）。并批准2023年第三季度财务报告对外报出。 表决结果：同意9票，反对0票，弃权0票。 备查 ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-078 号 一心堂药业集团股份有限公司 关于全资子公司天津鸿翔一心堂医药连锁有限公司收购天津福源 医药连锁有限公司 17 家门店资产及其存货的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （一）药品安全风险 公司所处的医药流通行业对药品安全的要求非常高，如果质量控制的某个环节出现 疏忽，影响药品安全，本公司将要承担相应的责任。同时，药品安全事故的发生将对本 公司的品牌和经营产生不利影响。自公司成立以来，对所有销售药品质量均进行严格的 把关，并根据《中华人民共和国药品管理法》、《中华人民共和国药品生产质量管理规 范》和《中华人民共和国药品经营质量管理规范》制定了《首营企业和首营品种审核制 度》、《药品进货管理程序》、《商品验收管理制度》、《供应商评审管理办法》、《三 级质量管理办法》、《质检抽（送）样管理办法》、《质量投诉管理办法》等一整套比 较完备的制度，在日常经营过程中，严格按照相关制度的规定执行，对所生产、采购药 品均进行严格的质量控制。但公司在对所采购药品 ...

一心堂药业集团股份有限公司 关于全资子公司四川一心堂医药连锁有限公司收购自贡市永康大 药房 16 家门店资产及其存货的公告 一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-079 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （一）药品安全风险 公司所处的医药流通行业对药品安全的要求非常高，如果质量控制的某个环节出现 疏忽，影响药品安全，本公司将要承担相应的责任。同时，药品安全事故的发生将对本 公司的品牌和经营产生不利影响。自公司成立以来，对所有销售药品质量均进行严格的 把关，并根据《中华人民共和国药品管理法》、《中华人民共和国药品生产质量管理规 范》和《中华人民共和国药品经营质量管理规范》制定了《首营企业和首营品种审核制 度》、《药品进货管理程序》、《商品验收管理制度》、《供应商评审管理办法》、《三 级质量管理办法》、《质检抽（送）样管理办法》、《质量投诉管理办法》等一整套比 较完备的制度，在日常经营过程中，严格按照相关制度的规定执行，对所生产、采购药 品均进行严格的质量控制。但公司在对所采购药品进行质检时，因无 ...

一心为民全心服务 关于全资子公司上海旭远消防技术服务有限公司 完成工商变更登记并取得营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开第六 届董事会第四次临时会议，审议通过《关于公司与上海旭远消防技术服务有限公司签订 股权转让协议的议案》，同意公司以自有资金人民币合计 1,315 万元收购上海旭远消防 技术服务有限公司（以下简称"旭远消防"）100%股权。本次收购完成后，公司持有旭 远消防 100%股权。具体内容详见公司 2023 年 8 月 26 日在指定信息披露媒体《证券时 报》、《中国证券报》、《证券日报》和巨潮资讯网（www.cninfo.com.cn）刊登的《关 于公司与上海旭远消防技术服务有限公司股东签订股权转让协议的公告》（公告编号： 2023-064）。 近日，公司已完成对旭远消防 100%股权的收购，现持有旭远消防 100%股权。旭远 消防已完成工商变更登记并取得由上海市奉贤区市场监督管理局核准换发的《营业执 照》，具体内容如下： 统一社会信用代 ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-077 号 一心堂药业集团股份有限公司 关于全资子公司山西鸿翔一心堂药业有限公司 收购平遥弘康等合计 29 家门店资产及其存货的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （一）药品安全风险 公司所处的医药流通行业对药品安全的要求非常高，如果质量控制的某个环节出现 疏忽，影响药品安全，本公司将要承担相应的责任。同时，药品安全事故的发生将对本 公司的品牌和经营产生不利影响。自公司成立以来，对所有销售药品质量均进行严格的 把关，并根据《中华人民共和国药品管理法》、《中华人民共和国药品生产质量管理规 范》和《中华人民共和国药品经营质量管理规范》制定了《首营企业和首营品种审核制 度》、《药品进货管理程序》、《商品验收管理制度》、《供应商评审管理办法》、《三 级质量管理办法》、《质检抽（送）样管理办法》、《质量投诉管理办法》等一整套比 较完备的制度，在日常经营过程中，严格按照相关制度的规定执行，对所生产、采购药 品均进行严格的质量控制。但公司在对所采购药品进行质检时，因 ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-076 号 关于全资子公司四川一心堂医药连锁有限公司 收购宣汉县百姓人药房等 27 家门店资产及其存货的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）第六届董事会第三次临时会议 审议通过《关于全资子公司四川一心堂医药连锁有限公司收购宣汉县百姓人药房等27 家门店资产及其存货的议案》，同意公司全资子公司四川一心堂医药连锁有限公司购买 成都宣汉县百姓人药房、四川济民堂大药房有限公司、宣汉县民济堂大药房（以下简称 "宣汉药房"）合计27家门店资产及其存货。并发布《关于全资子公司四川一心堂医药 连锁有限公司收购宣汉县百姓人药房等27家门店资产及其存货的公告》（公告编号： 2023-047号）。 截至本公告日，已按协议约定完成全部27家门店铺面租赁合同改签，门店固定资产 及存货盘点交接，并取得新的营业执照、药品经营许可证，门店已开始营业。 特此公告。 一心堂药业集团股份有限公司 董事会 2023 年 10 月 9 日 1/1 一心堂药 ...